REM Medical gets deeper into sleep with PsyPharma Tuscon acquisition
REM Medical Corporation, a US company with a network of clinics in the Greater Phoenix area focused on diagnosing and treating sleep-wake disorders, has boosted its research capabilities by acquiring the Tuscon, Arizona site of PsyPharma Global for an undisclosed sum.
PsyPharma is a contract research organisation (CRO) that conducts Phase II-IV clinical trials in the US and China for sleep disorders as well as psychiatric and neurological conditions. Renamed REM Medical Clinical Research, LLC, the acquired Tuscon site will work closely with pharmaceutical companies and CROs to provide Phase II-IV services evaluating drug compounds across a wide range of psychiatric and sleep indicators including insomnia and sleep apnoea, its new owner said.
REM has also retained an “exceptional” investigative, clinical and administrative team, led by principal investigator Dr Derek Loewy, with a track record of quality clinical trial activity, it noted. Before joining PsyPharma, Loewy was director of the Insomnia Program at the Sleep Clinic of San Francisco.
“Working with REM Medical will provide my research team with the systems and processes necessary to continue delivering quality services for our pharmaceutical sponsor organisations,” Loewy commented. “Our objective is to build from our Tucson location to expand local capacity, broaden our capabilities, and partner nationally with other leading researchers in the field.”
